NXGL NEXGEL INC

NEXGEL to Present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022

NEXGEL to Present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022

LANGHORNE, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced that Adam Levy, CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12th – 14th at the Lotte New York Palace Hotel in New York, NY.

H.C. Wainwright 24th Annual Global Investment Conference

Date: Wednesday, September 14, 2022

Time: 9:00 A.M. – 9:30 A.M. Eastern Time

Registration:

If you would like to book 1x1 investor meetings with NEXGEL, please contact your H.C. Wainwright representative or send an email to .

About NEXGEL, INC.

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contacts:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

Media Contacts:

Raquel Cona

KCSA Strategic Communications

212.896.1204



EN
07/09/2022

Underlying

NXGLNEXGEL INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXGEL INC

 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Reports Second Quarter 2025 Financial Results

NEXGEL Reports Second Quarter 2025 Financial Results Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-ge...

August 12, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

NEXGEL to Report Second Quarter 2025 Financial Results on August 12th Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardi...

NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:...

August 5, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Pr...

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 413,044 shares of its common stock (the “Shares”) at $2.30 a share. In a concurrent private placement, NEXGEL also agreed to issue to th...

August 1, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL and STADA AG Announce Expansion of Partnership for North Americ...

NEXGEL and STADA AG Announce Expansion of Partnership for North America LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks. As part of the agreement, STADA will advance $1 million to NEXGEL in non-dilutive...

July 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch